Adjuvant Abemaciclib Combined with Endocrine Therapy: Efficacy Results in monarchE Cohort 1

Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study

(2022) H.S. Rugo et al.   ANNALS OF ONCOLOGY

A real-world US study of recurrence risks using combined clinicopathological features in HR-positive, HER2-negative early breast cancer

(2022) Kristin M Sheffield et al.   Future Oncology

Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study

(2021) N. Harbeck et al.   ANNALS OF ONCOLOGY

Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE)

(2020) Stephen R. D. Johnston et al.   JOURNAL OF CLINICAL ONCOLOGY

Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials

(2015)   LANCET

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial

(2008)   LANCET ONCOLOGY